Business Context and Reporting Period
Company: Materialise NV
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter 2025 (Three months ended June 30, 2025)
Filing Date: July 24, 2025
Business Overview: Materialise provides software solutions and 3D printing services across healthcare, automotive, aerospace, and consumer goods sectors. The company operates through three segments: Materialise Medical, Materialise Software, and Materialise Manufacturing.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | Change |
|---|---|---|---|
| Total Revenue | 64,831 kEUR | 68,797 kEUR | -5.8% |
| Gross Profit | 37,778 kEUR | 39,227 kEUR | -3.7% |
| Gross Margin | 58.3% | 57.0% | +130 bps |
| Operating Profit | 2,730 kEUR | 3,801 kEUR | -28.2% |
| Net Profit | 199 kEUR | 3,875 kEUR | -94.9% |
| Adjusted EBITDA | 8,288 kEUR | 9,188 kEUR | -9.8% |
| Cash & Equivalents | 116,712 kEUR | 102,304 kEUR (Dec 31, 2024) | +14.1% |
| Gross Debt | 53,667 kEUR | 41,284 kEUR (Dec 31, 2024) | +30.0% |
| Net Cash Position | 63,045 kEUR | 61,020 kEUR (Dec 31, 2024) | +3.3% |
| Operating Cash Flow (Q2) | (27) kEUR | 8,400 kEUR | Negative |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 5.8% year-over-year. While the Medical segment grew 16.7% to 32,850 kEUR, this was offset by declines in Software (-12.1%) and Manufacturing (-24.9%).
- Profitability Compression: Net profit dropped significantly to 199 kEUR from 3,875 kEUR in Q2 2024. This was primarily driven by a deterioration in the net financial result, which swung from a 1,033 kEUR income in 2024 to a 3,052 kEUR loss in 2025 due to highly unfavorable unrealized exchange rate fluctuations.
- Segment Performance:
- Medical: Strong growth with Adjusted EBITDA margin expanding to 32.7%.
- Software: Revenue declined, but Adjusted EBITDA remained stable due to strict cost control, improving margin to 13.9%.
- Manufacturing: Significant contraction with revenue down 24.9% and Adjusted EBITDA turning negative at (807) kEUR (margin -3.6%).
- Balance Sheet: Gross debt increased by 12,383 kEUR compared to year-end 2024, though the net cash position remained positive and increased slightly.
Outlook, Risks, and Unusual Items
- Exchange Rate Impact: The filing highlights "highly unfavorable effects from unrealized exchange rate fluctuations" as a primary driver of the net financial loss and reduced net profit. Total comprehensive income was 823 kEUR, partially mitigated by exchange differences on translation of foreign operations.
- Cost Management: Operating expenses (R&D, S&M, G&A) decreased slightly by 0.8% in aggregate, indicating cost control efforts despite revenue declines in certain segments.
- Non-IFRS Measures: Management utilizes Adjusted EBIT and Adjusted EBITDA to evaluate performance, excluding share-based compensation, restructuring costs, and acquisition-related expenses. Adjusted EBIT margin decreased to 4.7% from 5.6%.
- Cash Flow: Operating cash flow for the quarter was effectively flat at (27) kEUR, a sharp contrast to the 8,400 kEUR generated in the prior year period. Capital expenditures for the quarter were 4,729 kEUR.
Investor Verification Checklist
- FX Sensitivity: Verify the specific currency exposures driving the 3,052 kEUR net financial loss and assess the sustainability of the current exchange rate environment.
- Manufacturing Segment Turnaround: Investigate the causes of the 24.9% revenue drop and negative Adjusted EBITDA in the Manufacturing segment to determine if this is a cyclical downturn or structural issue.
- Debt Utilization: Review the purpose of the increased gross debt (up 30% from year-end 2024) and the company's liquidity runway given the negative operating cash flow for the quarter.
- Medical Segment Growth: Confirm the drivers of the 16.7% revenue growth in the Medical segment to ensure it can offset weakness in other divisions.
- Working Capital: Analyze the significant decrease in trade payables and other payables (6,014 kEUR outflow in H1) impacting operating cash flow.